| __timestamp | BioCryst Pharmaceuticals, Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 2043000 |
| Thursday, January 1, 2015 | 1896000 | 3895000 |
| Friday, January 1, 2016 | 2699000 | 6552000 |
| Sunday, January 1, 2017 | 1702000 | 15066000 |
| Monday, January 1, 2018 | 471000 | 26348000 |
| Tuesday, January 1, 2019 | 4101000 | 33097000 |
| Wednesday, January 1, 2020 | 1676000 | 36272000 |
| Friday, January 1, 2021 | 7264000 | 52873000 |
| Saturday, January 1, 2022 | 6594000 | 57909000 |
| Sunday, January 1, 2023 | 4661000 | 72547000 |
| Monday, January 1, 2024 | 0 |
Unleashing the power of data
In the competitive world of biotechnology, cost efficiency is a critical factor for success. This analysis compares the cost of revenue efficiency between Exelixis, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Exelixis consistently outperformed BioCryst, with its cost of revenue peaking at approximately $72.5 million in 2023, a staggering 1,500% increase from 2014. In contrast, BioCryst's cost of revenue saw a more modest rise, reaching around $7.3 million in 2021, a 5,800% increase from its 2014 figure. This stark contrast highlights Exelixis's aggressive growth strategy and operational efficiency. As the biotech industry continues to evolve, understanding these financial dynamics is crucial for investors and stakeholders aiming to make informed decisions.
Cost of Revenue Comparison: AstraZeneca PLC vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue Comparison: Amgen Inc. vs Exelixis, Inc.
Comparing Cost of Revenue Efficiency: Teva Pharmaceutical Industries Limited vs BioCryst Pharmaceuticals, Inc.
Catalent, Inc. vs Exelixis, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Sarepta Therapeutics, Inc. vs Exelixis, Inc.
Cost of Revenue: Key Insights for Exelixis, Inc. and PTC Therapeutics, Inc.
Cost of Revenue Comparison: Exelixis, Inc. vs Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Exelixis, Inc. vs Xencor, Inc.
Cytokinetics, Incorporated vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Geron Corporation and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.